SGRY Stock Recent News

CHICAGO--(BUSINESS WIRE)--Oral Surgery Partners (“OSP”) announced today the closing of a $75 million credit expansion. The facility expansion was provided by the existing lending partners and will allow OSP to continue to grow through 2024 and beyond. “OSP's lenders continue to show strong support for the company due to its well-established track record and continued performance. We're excited to have like-minded lending partners who share the vision of providing excellent care in oral surgery.

Surgery Partners, Inc. (NASDAQ:SGRY ) Q1 2024 Results Conference Call May 4, 2024 8:30 AM ET Company Participants Dave Doherty - Chief Financial Officer Wayne DeVeydt - Executive Chairman Eric Evans - Chief Executive Officer Conference Call Participants Brian Tanquilut - Jefferies Whit Mayo - SVB Leerink Kevin Fischbeck - Bank of America Andrew Mok - Barclays Sarah James - Cantor Fitzgerald Gary Taylor - TD Cowen Bill Sutherland - The Benchmark Company Jason Cassorla - Citi Cal Sternick - JPMorgan Chase Ben Hendrix - RBC Capital Markets Operator Greetings. Welcome to Surgery Partners First Quarter 2024 Earnings Call.

Surgery Partners (SGRY) came out with quarterly earnings of $0.10 per share, beating the Zacks Consensus Estimate of $0.07 per share. This compares to earnings of $0.08 per share a year ago.

BRENTWOOD, Tenn., April 18, 2024 (GLOBE NEWSWIRE) -- Surgery Partners, Inc. (NASDAQ:SGRY) ("Surgery Partners" or the "Company"), a leading short-stay surgical facility owner and operator, announced the Company will release its first quarter 2024 results before the market opens on Tuesday, May 7, 2024, to be followed by a conference call at 8:30 a.m. (Eastern Time).

Investors interested in stocks from the Medical Services sector have probably already heard of Surgery Partners (SGRY) and Doximity (DOCS). But which of these two companies is the best option for those looking for undervalued stocks?

Surgery Partners (SGRY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

The mean of analysts' price targets for Surgery Partners (SGRY) points to a 39% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Follow Warren Buffett's latest tips and bet on top-ranked stocks like Microsoft (MSFT), Amazon.com (AMZN), Surgery Partners (SGRY) and Nvidia (NVDA).

While the top- and bottom-line numbers for Surgery Partners (SGRY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Surgery Partners (SGRY) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.37 per share. This compares to earnings of $0.27 per share a year ago.